Statins in High-Risk Chronic Obstructive Pulmonary Disease Outpatients: No Impact on Time to First Exacerbation and All-Cause Mortality – The STATUETTE Cohort Study

References

• The Lancet - Global Burden of Disease. Available from: https://www.thelancet.com/gbd. Accessed September 13, 2020.
   Google Scholar
• Maqsood U, Ho TN, Palmer K, et al. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;3. doi:10.1002/14651858.CD012930.pub2
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166(5):675–679. doi:10.1164/rccm.2112096
   PubMed Web of Science ®Google Scholar
• Mccarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;2.
   PubMedGoogle Scholar
• Vivodtzev I, Maltais F. Cardiovascular risk in COPD: searching for a culprit. Chest. 2020;157(4):753–754. doi:10.1016/j.chest.2020.01.008
   PubMed Web of Science ®Google Scholar
• Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1–16. doi:10.1177/1753465817750524
   Web of Science ®Google Scholar
• Sin DD, Man SFP. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. In: Proceedings of the American Thoracic Society; 2005:8–11.
   Google Scholar
• Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–639. doi:10.1016/S2213-2600(15)00241-6
   PubMed Web of Science ®Google Scholar
• Walsh A, Perrem L, Khashan AS, Henry MT, Ni Chroinin M. Statins versus placebo for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;7. doi:10.1002/14651858.CD011959.pub2
   Web of Science ®Google Scholar
• Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376–1384. doi:10.1016/j.rmed.2013.05.001
   PubMed Web of Science ®Google Scholar
• Ingebrigtsen TS, Marott JL, Nordestgaard BG, Lange P, Hallas J, Vestbo J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015;70(1):33–40. doi:10.1136/thoraxjnl-2014-205795
   PubMed Web of Science ®Google Scholar
• Lu Y, Chang R, Yao J, Xu X, Teng Y, Cheng N. Effectiveness of long-term using statins in COPD - a network meta-analysis. Respir Res. 2019;20(1):1–14. doi:10.1186/s12931-019-0984-3
   PubMedGoogle Scholar
• Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39(7 Suppl):22–25. doi:10.1177/1403494810387965
   PubMed Web of Science ®Google Scholar
• Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish national prescription registry. Int J Epidemiol. 2017;46(3):798. doi:10.1093/ije/dyw213
   PubMed Web of Science ®Google Scholar
• Ingebrigtsen TS, Marott JL, Lange P, Hallas J, Nordestgaard BG, Vestbo J. Medically treated exacerbations in COPD by GOLD 1–4: a valid, robust, and seemingly low-biased definition. Respir Med. 2015;109(12):1562–1568. doi:10.1016/j.rmed.2015.10.015
   PubMed Web of Science ®Google Scholar
• Reilev M, Pottegård A, Lykkegaard J, Søndergaard J, Ingebrigtsen TS, Hallas J. Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPD. Respirology. 2019;24(12):1183–1190. doi:10.1111/resp.13620
   PubMed Web of Science ®Google Scholar
• GOLD guidelines. Availble from: https://goldcopd.org/gold-reports/. Accessed October 25, 2020.
   Google Scholar
• Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2008;167(4):492–499. doi:10.1093/aje/kwm324
   PubMed Web of Science ®Google Scholar
• van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1–67.
   Web of Science ®Google Scholar
• Wouters EFM. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:26–33. doi:10.1513/pats.200408-039MS
   PubMedGoogle Scholar
• Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–2653. doi:10.1056/NEJMoa032158
   PubMed Web of Science ®Google Scholar
• Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867–874. doi:10.1164/rccm.200604-506OC
   PubMed Web of Science ®Google Scholar
• White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease • 6: the aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax. 2003;58(1):73–80. doi:10.1136/thorax.58.1.73
   PubMed Web of Science ®Google Scholar
• Kunz LIZ, Ten Hacken N, Lapperre TS, et al. Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids. Eur Respir J. 2017;49(6):1700848. doi:10.1183/13993003.00848-2017
   PubMed Web of Science ®Google Scholar
• Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev. 2010;23(3):590–615. doi:10.1128/CMR.00078-09
   PubMed Web of Science ®Google Scholar
• Cheng SL. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis. Int J COPD. 2018;13:2775–2784. doi:10.2147/COPD.S175017
   Google Scholar
• Yndestad A, Damås JK, Øie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure - the whys and wherefores. Heart Fail Rev. 2006;11(1):83–92. doi:10.1007/s10741-006-9196-2
   PubMed Web of Science ®Google Scholar
• Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23):2201–2210. doi:10.1056/NEJMoa1403086
   PubMed Web of Science ®Google Scholar
• Citgez E, Van Der Palen J, Koehorst-Ter Huurne K, Movig K, Van Der Valk P, Brusse-Keizer M. Statins and morbidity and mortality in COPD in the COMIC study: a prospective COPD cohort study. BMJ Open Respir Res. 2016;3(1):1–7. doi:10.1136/bmjresp-2016-000142
   Google Scholar
• Lin CM, Yang TM, Yang YH, et al. Statin use and the risk of subsequent hospitalized exacerbations in COPD patients with frequent exacerbations. Int J Chron Obstruct Pulmon Dis. 2020;15:289–299. doi:10.2147/COPD.S229047
   PubMed Web of Science ®Google Scholar
• Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med. 2013;126(7):598–606.e2. doi:10.1016/j.amjmed.2013.01.036
   PubMed Web of Science ®Google Scholar
• Raymakers AJN, Sadatsafavi M, Sin DD, De Vera MA, Lynd LD. The impact of statin drug use on all-cause mortality in patients with COPD: a Population-Based Cohort Study. Chest. 2017;152(3):486–493. doi:10.1016/j.chest.2017.02.002
   PubMed Web of Science ®Google Scholar
• Godtfredsen NS, Lam TH, Hansel TT, et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J. 2008;32(4):844–853. doi:10.1183/09031936.00160007
   PubMed Web of Science ®Google Scholar
• Ching SM, Chia YC, Lentjes MAH, Luben R, Wareham N, Khaw KT. FEV1 and total cardiovascular mortality and morbidity over an 18 years follow-up population-based prospective EPIC-NORFOLK Study. BMC Public Health. 2019;19(1):1–10. doi:10.1186/s12889-019-6818-x
   PubMedGoogle Scholar
• Ekström M, Hermansson A, Ström K. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease: a time-dependent analysis. Am J Respir Crit Care Med. 2013;187:715–720. doi:10.1164/rccm.201208-1565OC
   PubMed Web of Science ®Google Scholar
• Bartziokas K, Papaioannou AI, Minas M, et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study. Pulm Pharmacol Ther. 2011;24(5):625–631. doi:10.1016/j.pupt.2011.06.003
   PubMed Web of Science ®Google Scholar
• Moosavi SA, Raji H, Faghankhani M, Yazdani R, Esmaeili M. Evaluation of the effects of atorvastatin on the treatment of secondary pulmonary hypertension due to chronic obstructive pulmonary diseases: a randomized controlled trial. Iran Red Crescent Med J. 2013;15(8):649–654. doi:10.5812/ircmj.8267
   PubMed Web of Science ®Google Scholar
• Lahousse L, Loth DW, Joos GF, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther. 2013;26(2):212–217. doi:10.1016/j.pupt.2012.10.008
   PubMed Web of Science ®Google Scholar